Clavulanic acid

Generic Name
Clavulanic acid
Brand Names
Clavulin, Augmentin
Drug Type
Small Molecule
Chemical Formula
C8H9NO5
CAS Number
58001-44-8
Unique Ingredient Identifier
23521W1S24
Background

Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus.When it is combined with amoxi...

Indication

Clavulanic acid combined with other antibiotics is indicated to prevent the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects.

The following conditions, when they produced beta-lactamases, have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acid:
...

Associated Conditions
Infection Due to Escherichia Coli, Skin and skin structure infections, Acute Uncomplicated Pyelonephritis, Bronchitis, Haemophilus Influenzae, Lower Respiratory Infection, Otitis Media (OM), Moraxella catarrhalis, Upper Respiratory Tract Infection, Acute Cystitis, Cysto-Urethritis, Bone and Joint Infections, Sinusitis, Intraabdominal Infections, Tonsillitis, Proteus mirabilis, Lower Respiratory Tract Infection (LRTI), Neisseria Gonorrhoeae Infection, Susceptible Bacterial Infections, Pharyngitis, Bacterial infection due to streptococcus, group A, Urinary Tract Infection, Septicemia, Bacterial Infections, Bacterial Pneumonia, Streptococcus Pneumoniae, Gynecological Infection
Associated Therapies
-
observervoice.com
·

Surge in Pharma Sales Driven by Demand

The Indian pharmaceutical retail market rebounded in November with double-digit growth, driven by increased demand for dermatological, cardiac, and respiratory medications. Foracort, an asthma drug, topped sales at ₹82 crore. Urology, dermatology, cardiology, and pain relief therapies saw significant growth. Sun Pharma leads with an 8% market share. Analysts predict high-single-digit growth through 2025, driven by price increases and new product launches.

Indian Pharma Market Posts Robust 10.7% Growth in November, Foracort Tops Sales

Foracort led with Rs 82 crore in sales, followed by Augmentin and Glycomet GP. Urology grew 18%, dermatology 16%, and cardiac/pain relief 13%. Respiratory therapies grew due to air pollution. Cold Preparation Ethicals and paracetamol subgroups performed well. VMN and dermatology segments grew significantly. Sun Pharma led with an 8% market share. 746 new SKUs were introduced, and 3,024 SKUs saw PTR changes.

Amid pollution woes, Asthma drug demand drives pharma retail market growth in November

India's organized pharma retail market grew 11% in November, led by derma, cardiac, and respiratory drugs. Foracort topped sales at Rs 82 crore, followed by Augmentin and Glycomet GP. Urology, derma, cardiac, and pain-relief segments grew 18%, 16%, 13%, and 13% respectively. Sun Pharma led with an 8% market share, while domestic companies slightly outpaced MNCs. The market is expected to grow in high single digits by 2025, driven by price increases and new launches, including GLP-1 drugs.

Pharma market rebounds, asthma drug top seller

Strong demand for derma and cardiac drugs drove pharma retail market growth in Nov, with Foracort sales topping at Rs 82 crore. Urology led with 18% growth, followed by derma, cardiac, and pain-relief at 16%, 13%, and 13%. Sun Pharma led with 8% share, while domestic companies grew nearly 11% and MNCs over 10%. The market is expected to grow by high-single digits in 2025, with Indian companies launching GLP-1 drugs.
telanganatoday.com
·

TSDCA seizes Rs 1.33 crore worth of antibiotics to be exported to Russia

TSDCA seized Rs 1.33 crore worth of antibiotics falsely labeled as manufactured by Jodas Expoim Pvt. Ltd. and exported to Russia, violating the Drugs and Cosmetics Act, 1940.
chemindigest.com
·

Pharmaceutical Plants Launched Under PLI Scheme to Reduce Import

Govt inaugurates two greenfield plants under PLI scheme to reduce pharma imports, focusing on penicillin G, 6-APA, and clavulanic acid production. These plants aim to cut import dependence by 50% for penicillin G and 6-APA, and by 40% for clavulanic acid, enhancing India's self-sufficiency in drug production.
contagionlive.com
·

SURE1 and REASSURE Trials Paved Way for FDA Approval of Orlynvah

Iterum Therapeutics' Orlynvah approved for uUTIs, based on SURE1 and REASSURE trials. Orlynvah showed superiority over ciprofloxacin in resistant infections but not in susceptible ones, due to cipro's prolonged effect on bacterial flora. Cipro's safety issues led to its demotion as a first-line agent. REASSURE trial confirmed Orlynvah's efficacy in susceptible populations and non-inferiority overall, crucial for empiric therapy in community settings. Iterum seeks a strategic partner for Orlynvah's launch, aiming to address unmet needs and antibiotic resistance.
finance.yahoo.com
·

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves ...

Iterum Therapeutics received FDA approval for Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections in adult women with limited oral treatment options. This marks the first FDA-approved product for Iterum, based on Phase 3 trials showing safety and efficacy compared to ciprofloxacin and Augmentin.

FDA approves Iterum's ORLYNVAH NDA for uUTI treatment

FDA approves Iterum Therapeutics' ORLYNVAH for treating uUTIs in adult women, offering a new oral penem antibiotic for resistant microorganisms.

FDA approves Iterum's Orlynvah for urinary tract infection

Iterum Therapeutics receives FDA approval for Orlynvah, an oral penem antibiotic for treating uUTIs in adult women, marking the first approval for the company. Orlynvah targets infections caused by bacteria like E. coli, K. pneumoniae, and P. mirabilis, offering an alternative for patients with limited oral treatment options. The approval follows successful Phase 3 trials demonstrating safety and efficacy.
© Copyright 2024. All Rights Reserved by MedPath